-continued

<400> SEQUENCE: 7

Arg Pro Lys Pro Tyr Ala Xaa Trp Met Lys
1 5 10

1. A compound according to Formula I:



I

Wherein

R^1 is:

H,

C_{1-4} alkyl optionally substituted with one or more independently selected R^4 groups,

C_{3-7} monocyclic cycloalkyl optionally substituted with one or more independently selected R^4 groups,

4-7 membered monocyclic heterocycloalkyl comprising 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted with one or more independently selected C_{1-4} alkyl, —C(═O)C_{1-4} alkyl, or —C(═O)OC_{1-4} alkyl,

phenyl optionally substituted with one or more independently selected R^5 groups,

phenyl fused to a 5-6 membered monocyclic heterocycloalkyl comprising 1, 2 or 3 heteroatoms independently selected from N, O, and S, which heterocycloalkyl is optionally substituted with one or more ═O,

5-6 membered monocyclic heteroaryl comprising 1 or 2 heteroatoms independently selected from N, O, and S, optionally substituted with one or more independently selected R^5 groups;

R^2 is independently selected from:

H,

—OH,

C_{1-4} alkoxy, and

C_{1-4} alkyl optionally substituted with one

OH,

—CN,

C_{1-4} alkoxy optionally substituted with one phenyl, and

5-6 membered monocyclic heteroaryl comprising 1 or 2 heteroatoms independently selected from N, O, and S, optionally substituted with one or more independently selected C_{1-4} alkyl;

each R^{3a}, and R^{3b} is independently selected from H, and

C_{1-4} alkyl optionally substituted with one or more halo;

Cy is

6-10 membered monocyclic or fused bicyclic aryl,

5-10 membered monocyclic or fused bicyclic heteroaryl comprising 1, 2 or 3 heteroatoms independently selected from N, O, and S;

R^4 is

halo,

OH,

—CN,

C_{1-4} alkyl,

C_{1-4} alkoxy optionally substituted with one C_{1-4} alkoxy, or phenyl,

C_{1-4} thioalkoxy,

4-7-membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, S, and O, optionally substituted with one or more halo, or —C(═O)OC_{1-4} alkyl,

phenyl,

—S(═O)$_2$$C_{1-4}$ alkyl

—C(═O)OR^{7a}

—C(═O)N$R^{7b}$$R^{7c}$

—NHC(═O)OR^{7d}

—NHC(═O)R^{7e}

—N$R^{8a}$$R^{8b}$;

each R^5 is

halo,

OH,

—CN,

C_{1-4} alkyl optionally substituted with one or more independently selected halo, —N$R^{9a}$$R^{9b}$, or —C(═O)N$R^{9c}$$R^{9d}$,

C_{1-4} alkoxy optionally substituted with —N$R^{9e}$$R^{9f}$, or —S(═O)$_2$$C_{1-4}$ alkyl;

each R^{6a} is

C_{2-4} alkyl optionally substituted with one or more halo,

C_{1-4} alkoxy optionally substituted with one or more halo,

the subscript n is 0, 1, 2 or 3

each R^{6b} is independently selected from

halo,

—CN,

—NO_2,

—C_{1-4} alkyl,

—C_{1-4} alkoxy

5-10 membered monocyclic or fused bicyclic heteroaryl comprising 1, 2 or 3 heteroatoms independently selected from N, O, and S, optionally substituted with one or more independently selected halo, C_{1-4} alkyl, or C_{1-4} alkoxy, and

—N$R^{9g}$$R^{9h}$;

each R^{7a}, R^{7b}, R^{7c}, R^{7d}, or R^{7e}, is H, or C_{1-4} alkyl optionally substituted with OH or C_{1-4} alkoxy;

each R^{8a}, or R^{8b} is independently selected from H, and C_{1-4} alkyl optionally substituted with OH, C_{1-4} alkoxy, or phenyl;

each R^{9a}, R^{9b}, R^{9c}, R^{9d}, R^{9e}, R^{9f}, R^{9g}, R^{9h} is independently selected from H, and

C_{1-4} alkyl;

or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof; or a biologically active metabolite thereof;